Information Provided By:
Fly News Breaks for August 2, 2016
NXTM
Aug 2, 2016 | 07:50 EDT
Canaccord raised its price target on NxStage Medical to $26 from $22 as they believe its momentum in the core products business is sustainable and supports upside for 2016. The firm also expects operating leverage and a strong pipeline of catalysts to keep investors engaged in the story. Canaccord reiterated its Buy rating on NxStage Medical shares.
News For NXTM From the Last 2 Days
There are no results for your query NXTM